Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Qualigen Therapeutics, Inc. (QLGN) had Return on Tangible Equity of -229.90% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-6.35M |
|
-- |
|
-- |
|
$5.76M |
|
$-5.76M |
|
$-0.39M |
|
$-6.15M |
|
$-6.15M |
|
$-6.16M |
|
$-6.16M |
|
$-6.26M |
|
$-6.16M |
|
$-5.76M |
|
$-5.15M |
|
0.36M |
|
0.36M |
|
$-17.55 |
|
$-17.55 |
|
| Balance Sheet Financials | |
$4.68M |
|
-- |
|
$0.00M |
|
$4.69M |
|
$2.01M |
|
-- |
|
-- |
|
$2.01M |
|
$-3.04M |
|
$2.68M |
|
$2.68M |
|
0.74M |
|
| Cash Flow Statement Financials | |
$-6.33M |
|
$-1.91M |
|
$9.01M |
|
$0.40M |
|
$1.17M |
|
$0.77M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
202.78% |
|
|
Return on Tangible Equity |
-229.90% |
-131.42% |
|
-229.90% |
|
$3.64 |
|
$-17.50 |
|
$-17.50 |
|